NCT/Study#
NCT06556563 /
EF-41-KEYNOTE-D58
Tumor Treating Fields (TTFields) with maintenance temozolomide (TMZ) and pembrolizumab versus TTFields concomitant with maintenance TMZ and placebo in participants with newly diagnosed glioblastoma. Keynote D58
DISEASE GROUP:
Neuro-Oncology
current phase:
Phase III
STUDY STATUS:
Enrolling
Location:
Hackensack, NJ
For More information:
